10058-F4A c-Myc inhibitor and apoptosis inducer

10058-F4 (CAS 403811-55-2)

10058-F4 | CAS 403811-55-2 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_21, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_213577, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 71ms
  • REVIEWS, PRODUCT
Synonym: 5-[(4-Ethylphenyl)methylene]-2-thioxo-4-thiazolidinone
Application: A c-Myc inhibitor and apoptosis inducer
CAS Number: 403811-55-2
Purity: ≥95%
Molecular Weight: 249.35
Molecular Formula: C12H11NOS2
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

10058-F4 is a c-Myc inhibitor that prevents c-Myc/Max dimerization. c-Myc is a proto-oncogene that plays an important role in cell proliferation, differentiation, and apoptosis. 10058-F4 has been shown to arrest cell growth at G0/G1 phase. Experiments show that extended exposure to 10058-F4 causes apoptosis via upregulation of Bax, expression of cytoplasmic Cytochrome C, down-regulation of Bcl-2, and cleavage of caspase-3,-7, and -9. This compound has been found to also upregulate cyclin-dependent kinase inhibitors, p21 and p27.


References

1. Huang, M.J., et al. 2006. Exp. Hematol. 34: 1480-1489. PMID: 17046567
2. Lin, C.P., et al. 2007. Anticancer Drugs. 18: 161-170. PMID: 17159602
3. Guo, J., et al. 2009. Cancer Chemother. Pharmacol. 63: 615-625. PMID: 18509642

Physical State :
Solid
Solubility :
Soluble in DMSO (up to 100 mM) or ethanol (up to 20 mM).
Storage :
Store at 4° C
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
1271002
SMILES :
CCC1=CC=C(C=C1)/C=C/2\\C(=O)NC(=S)S2

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

10058-F4  Product Citations

See how others have used 10058-F4. Click on the entry to view the PubMed entry .

Citations 1 to 4 of 4 total

PMID: # 28402964  Ren, X. et al. 2017. Oncotarget. 8: 40958-40966.

PMID: # 26312753  Mushtaq, M. et al. 2015. PLoS ONE. 10: e0136142.

PMID: # 23857601  Xu, M. et al. 2013. Clin. Cancer Res. 19: 4697-705.

PMID: # 23389829  Han, H. et al. 2013. Hepatology. 57: 2378-89.

Citations 1 to 4 of 4 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 86ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Hollen Hollen, T. et al. (PubMed 26087190) found that myeloma cell line sensitivity to the Myc inhibitor 10058-F4 correlated with Myc expression, supporting that the activity of 10058-F4 was through specific inhibition of Myc. -SCBT Publication Review
Date published: 2015-03-11
  • y_2019, m_9, d_22, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_213577, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 96ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.